• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

作者信息

Matsumoto Kazuaki, Takesue Yoshio, Ohmagari Norio, Mochizuki Takahiro, Mikamo Hiroshige, Seki Masafumi, Takakura Shunji, Tokimatsu Issei, Takahashi Yoshiko, Kasahara Kei, Okada Kenji, Igarashi Masahiro, Kobayashi Masahiro, Hamada Yukihiro, Kimura Masao, Nishi Yoshifumi, Tanigawara Yusuke, Kimura Toshimi

机构信息

Committee of Practice Guidelines for TDM of Antimicrobial Agents, Japanese Society of Chemotherapy, Nichinai Kaikan B1, 3-28-8 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.

出版信息

J Infect Chemother. 2013 Jun;19(3):365-80. doi: 10.1007/s10156-013-0599-4. Epub 2013 May 15.

DOI:10.1007/s10156-013-0599-4
PMID:23673472
Abstract
摘要

相似文献

1
Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.万古霉素治疗药物监测实践指南：日本化疗学会和日本治疗药物监测学会的共识性综述
J Infect Chemother. 2013 Jun;19(3):365-80. doi: 10.1007/s10156-013-0599-4. Epub 2013 May 15.
2
[Glycopeptides (vancomycin, teicoplanin)].[糖肽类（万古霉素、替考拉宁）]
Nihon Rinsho. 2004 Dec;62 Suppl 12:423-6.
3
An update on vancomycin dosing and monitoring practices in hemodialysis patients.血液透析患者万古霉素给药与监测实践的最新进展
CANNT J. 2013 Oct-Dec;23(4):25-7; quiz 28-9.
4
Appropriateness of vancomycin therapeutic drug monitoring and its outcomes among non-dialysis patients in a tertiary hospital in Singapore.新加坡一家三级医院非透析患者中万古霉素治疗药物监测的适宜性及其结果
Int J Clin Pharm. 2018 Oct;40(5):977-981. doi: 10.1007/s11096-018-0670-4. Epub 2018 Jun 12.
5
Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.伏立康唑治疗药物监测实践指南：日本化疗学会和日本治疗药物监测学会的共识性综述
J Infect Chemother. 2013 Jun;19(3):381-92. doi: 10.1007/s10156-013-0607-8. Epub 2013 May 15.
6
Understanding vancomycin levels.了解万古霉素水平。
Nursing. 2013 Nov;43(11):66-7. doi: 10.1097/01.NURSE.0000435209.34142.0e.
7
Vancomycin levels: to draw or not to draw.万古霉素血药浓度：是否进行检测。
S D J Med. 1998 Jun;51(6):195-6.
8
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.成人患者万古霉素的治疗监测：美国卫生系统药师协会、美国传染病学会和传染病药师协会的共识综述
Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98. doi: 10.2146/ajhp080434.
9
Therapeutic drug monitoring of vancomycin in patients receiving haemodialysis: time for a change.接受血液透析患者万古霉素的治疗药物监测：是时候做出改变了。
J Clin Pathol. 2006 Jun;59(6):666-7.
10
Vancomycin dosing and monitoring.万古霉素的给药与监测。
Med Lett Drugs Ther. 2009 Apr 6;51(1309):25.

引用本文的文献

1
Time-to-recovery from severe pneumonia and its predictors among children 2-59 months of age admitted to the pediatric ward of Jimma University Medical Center, Southwest Ethiopia, 2023: A retrospective cohort study.2023年埃塞俄比亚西南部吉马大学医学中心儿科病房收治的2至59个月大儿童严重肺炎康复时间及其预测因素：一项回顾性队列研究
PLoS One. 2025 Apr 15;20(4):e0316839. doi: 10.1371/journal.pone.0316839. eCollection 2025.
2
Clinical validation of an innovative dried whole-blood spot method to quantify simultaneously vancomycin and creatinine in adult patients.一种创新的干血斑法用于同时定量成年患者万古霉素和肌酐的临床验证。
J Antimicrob Chemother. 2025 Apr 2;80(4):1097-1107. doi: 10.1093/jac/dkaf041.
3
Factors Affecting Vancomycin Trough Concentration; a Population Pharmacokinetic Model in Non-Critical Care Saudi Patients.
影响万古霉素谷浓度的因素；沙特非重症监护患者的群体药代动力学模型
Drug Des Devel Ther. 2024 Dec 21;18:6185-6198. doi: 10.2147/DDDT.S496512. eCollection 2024.
4
Systematic review and meta-analysis of vancomycin therapeutic level for treatment of vancomycin-sensitive enterococcal infections.万古霉素治疗敏感肠球菌感染的治疗水平的系统评价和荟萃分析。
Br J Clin Pharmacol. 2025 Apr;91(4):1250-1262. doi: 10.1111/bcp.16362. Epub 2024 Dec 8.
5
Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian Estimation.采用贝叶斯估计评估万古霉素 AUC 时，确定需要两点采血（峰和谷）而不是单点采血（仅谷值）的患者。
Pharm Res. 2024 Nov;41(11):2161-2171. doi: 10.1007/s11095-024-03781-4. Epub 2024 Oct 21.
6
Impact of the First Twenty-Four-Hour Area Under the Concentration-Time Curve/Minimum Inhibitory Concentration of Vancomycin on Treatment Outcomes in Patients With Methicillin-Resistant Bacteremia.万古霉素浓度-时间曲线下第一个24小时面积/最低抑菌浓度对耐甲氧西林菌血症患者治疗结局的影响
J Clin Med Res. 2024 Aug;16(7-8):325-334. doi: 10.14740/jocmr5238. Epub 2024 Aug 10.
7
Predictive Value of Vancomycin AUC/MIC Ratio for 30-day Mortality in Patients with Severe or Complicated Methicillin-Resistant Staphylococcus aureus Infections: A Multicenter Retrospective Study.预测万古霉素 AUC/MIC 比值对严重或复杂耐甲氧西林金黄色葡萄球菌感染患者 30 天死亡率的价值：一项多中心回顾性研究。
Pharm Res. 2024 Jul;41(7):1381-1389. doi: 10.1007/s11095-024-03728-9. Epub 2024 Jun 17.
8
Antimicrobial Multidrug Resistance: Clinical Implications for Infection Management in Critically Ill Patients.抗菌多药耐药性：对重症患者感染管理的临床意义
Microorganisms. 2023 Oct 16;11(10):2575. doi: 10.3390/microorganisms11102575.
9
Status and Quality of Guidelines for Therapeutic Drug Monitoring Based on AGREE II Instrument.基于 AGREE II 工具的治疗药物监测指南的现状和质量。
Clin Pharmacokinet. 2023 Sep;62(9):1201-1217. doi: 10.1007/s40262-023-01283-x. Epub 2023 Jul 25.
10
Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative study.替考拉宁与万古霉素治疗糖肽类敏感粪肠球菌菌血症：倾向评分调整的非劣效性比较研究。
J Antimicrob Chemother. 2023 May 3;78(5):1231-1240. doi: 10.1093/jac/dkad079.